- Patent Title: Co-crystal of the PAR-1 receptor antagonists vorapaxar and aspirin
-
Application No.: US14905193Application Date: 2014-07-17
-
Publication No.: US09604971B2Publication Date: 2017-03-28
- Inventor: Scott Trzaska , Alicia V. Duran-Capece , Matthew Lamm
- Applicant: ARALEZ PHARMACEUTICALS TRADING DAC
- Applicant Address: IE Dublin
- Assignee: ARALEZ PHARMACEUTICALS TRADING DAC
- Current Assignee: ARALEZ PHARMACEUTICALS TRADING DAC
- Current Assignee Address: IE Dublin
- Agency: Parker Highlander PLLC
- International Application: PCT/US2014/046929 WO 20140717
- International Announcement: WO2015/013083 WO 20150129
- Main IPC: C07D405/06
- IPC: C07D405/06 ; A61K31/443 ; A61K31/616 ; C07C69/157
Abstract:
This invention relates to a co-crystal of vorapaxar and aspirin. The inventive co-crystal antagonizes the PAR-1 receptor. This invention also provides for pharmaceutical compositions comprising the inventive co-crystal as well as potentially to methods for the treatment, amelioration or prevention of conditions that could be treated by antagonizing the PAR-1 receptor.
Public/Granted literature
- US20160159779A1 CO-CRYSTAL OF THE PAR-1 RECEPTOR ANTAGONISTS VORAPAXAR AND ASPRIN Public/Granted day:2016-06-09
Information query
